caa a22 4500 606158758 CHVBK 20210128100621.0 cr unu---uuuuu 210128e20150401xx s 000 0 eng 10.1007/s10557-015-6582-9 doi (NATIONALLICENCE)springer-10.1007/s10557-015-6582-9 Update of Clinical Trials of Anti-PCSK9 Antibodies [Elektronische Daten] [Na-Qiong Wu, Sha Li, Jian-Jun Li] Hyperlipidemia is a predominant risk factor for cardiovascular disease (CVD). Statins have been successfully used to treat patients with dyslipidemia and decrease the events of CVD in addition to application of various other non-statin-lowering cholesterol agents, such as ezetimibe and niacin. However, there are still residual risks in patients with atherosclerotic CVD. Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9), which was first identified in 2003, has been suggested to play an important role in the metabolism of low-density lipoprotein cholesterol (LDL-C). PCSK9 degrades the LDL-receptor, which may be pharmacologically targeted to improve the lipoprotein profile and future cardiovascular outcomes in patients with dyslipidemia. Several approaches to inhibiting PCSK9 activity have been theoretically proposed. Among them, monoclonal antibodies have been considered as the most promising strategy because of their large effect on lowering lipids as monotherapy and in combination with statins or ezetimibe. In this review, we mainly focus on the current status of monoclonal antibodies of PCSK9 and clinical trial results for an update on clinical application of monoclonal antibodies of PCSK9. The particular effects of monoclonal antibodies of PCSK9 on lipid profiles are also discussed. Springer Science+Business Media New York, 2015 Proprotein convertase subtilisin/kexin type 9 nationallicence Hyperlipidemia nationallicence Cardiovascular diseases nationallicence Antibodies nationallicence Clinical trials nationallicence Wu Na-Qiong Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, 167 BeiLiShi Road, 100037, Beijing, China aut Li Sha Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, 167 BeiLiShi Road, 100037, Beijing, China aut Li Jian-Jun Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, 167 BeiLiShi Road, 100037, Beijing, China aut Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/2(2015-04-01), 159-169 0920-3206 29:2<159 2015 29 10557 https://doi.org/10.1007/s10557-015-6582-9 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10557-015-6582-9 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wu Na-Qiong Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, 167 BeiLiShi Road, 100037, Beijing, China aut NATIONALLICENCE 700 1- Li Sha Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, 167 BeiLiShi Road, 100037, Beijing, China aut NATIONALLICENCE 700 1- Li Jian-Jun Division of Dyslipidemia, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, 167 BeiLiShi Road, 100037, Beijing, China aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Springer US; http://www.springer-ny.com 29/2(2015-04-01), 159-169 0920-3206 29:2<159 2015 29 10557